Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Receives $3.49 Consensus Target Price from Analysts

Share on StockTwits

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) has received an average recommendation of “Hold” from the seven research firms that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $3.49.

A number of research firms recently weighed in on CNAT. Zacks Investment Research raised shares of Conatus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a report on Thursday, August 15th. HC Wainwright reissued a “hold” rating and issued a $1.50 target price on shares of Conatus Pharmaceuticals in a report on Friday, May 3rd.

Shares of CNAT stock traded up $0.01 on Thursday, reaching $0.33. The company’s stock had a trading volume of 400 shares, compared to its average volume of 652,502. The stock’s fifty day simple moving average is $0.31 and its 200-day simple moving average is $1.07. Conatus Pharmaceuticals has a 1 year low of $0.25 and a 1 year high of $6.74. The company has a market capitalization of $10.78 million, a price-to-earnings ratio of -0.55 and a beta of 2.18.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.10. Conatus Pharmaceuticals had a negative net margin of 42.26% and a negative return on equity of 60.61%. The firm had revenue of $10.79 million during the quarter, compared to analyst estimates of $7.00 million. On average, research analysts expect that Conatus Pharmaceuticals will post -0.37 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in CNAT. Wedbush Securities Inc. bought a new position in Conatus Pharmaceuticals in the first quarter worth about $46,000. D. E. Shaw & Co. Inc. raised its holdings in Conatus Pharmaceuticals by 50.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 62,163 shares of the biotechnology company’s stock worth $108,000 after purchasing an additional 20,826 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Conatus Pharmaceuticals by 90.7% in the second quarter. Acadian Asset Management LLC now owns 467,425 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 222,347 shares in the last quarter. Hikari Power Ltd raised its holdings in Conatus Pharmaceuticals by 19.8% in the first quarter. Hikari Power Ltd now owns 200,488 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 33,200 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Conatus Pharmaceuticals by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 33,827 shares in the last quarter. Hedge funds and other institutional investors own 24.70% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

See Also: Stop Order Uses For Individual Investors

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases Position in VANGUARD ADMIRA/S&P 500 VALUE IX FD
JPMorgan Chase & Co. Increases Position in VANGUARD ADMIRA/S&P 500 VALUE IX FD
Brookfield Asset Management Inc. Purchases 972 Shares of Antero Midstream GP LP
Brookfield Asset Management Inc. Purchases 972 Shares of Antero Midstream GP LP
BP Capital Fund Advisors LLC Increases Stake in Antero Midstream GP LP
BP Capital Fund Advisors LLC Increases Stake in Antero Midstream GP LP
TESSCO Technologies  Rating Lowered to Hold at ValuEngine
TESSCO Technologies Rating Lowered to Hold at ValuEngine
Viper Energy Partners  Price Target Raised to $48.00
Viper Energy Partners Price Target Raised to $48.00
Wayfair Inc  CTO John Champlin Mulliken Sells 3,168 Shares
Wayfair Inc CTO John Champlin Mulliken Sells 3,168 Shares


© 2006-2019 Ticker Report